MARKET

AKBA

AKBA

Akebia
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.360
+0.140
+4.35%
After Hours: 3.360 0 0.00% 16:09 11/15 EST
OPEN
3.260
PREV CLOSE
3.220
HIGH
3.425
LOW
3.230
VOLUME
1.71M
TURNOVER
--
52 WEEK HIGH
10.45
52 WEEK LOW
2.990
MARKET CAP
399.65M
P/E (TTM)
-1.3821
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of AKBA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

AKBA News

  • Tracking Seth Klarman's Baupost Group Holdings - Q3 2019 Update
  • Seeking Alpha - Article.1d ago
  • The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing
  • Benzinga.3d ago
  • The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher
  • Benzinga.4d ago
  • Akebia Therapeutics Inc. (AKBA) CEO John Butler on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.5d ago

More

Industry

Biotechnology & Medical Research
+1.25%
Pharmaceuticals & Medical Research
+1.34%

Hot Stocks

Name
Price
%Change

About AKBA

Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company's lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD). It is involved in developing vadadustat as an oral therapy. The Company's vadadustat is a HIF-prolyl-hydroxylase (HIF-PH) inhibitor in Phase III development for the treatment of anemia of CKD. In addition to vadadustat, the Company is engaged in developing a HIF-based portfolio of product candidates that target serious diseases of unmet need. Its portfolio includes product candidates developed internally, such as AKB-6899, as well as in-licensed product candidates, including AKB-5169. AKB-5169 is a preclinical compound in development as an oral treatment for inflammatory bowel disease (IBD).
More

Webull offers Akebia Therapeutics Inc (AKBA) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.